Parent page: Personalized Treatment Plan
Extracellular vesicles (EVs), including exosomes, microvesicles, and apoptotic bodies, represent a promising native nanoparticle platform for CNS drug delivery. Engineering EVs for targeted CNS delivery requires optimization of surface ligands for BBB crossing, cargo loading strategies for therapeutic payloads, and manufacturing scalability. This section covers advanced EV engineering approaches for CBS/PSP therapeutic applications.
BBB Crossing Strategies:
| Strategy | Target | Mechanism | Evidence Level |
|---|---|---|---|
| LDL Receptor Targeting | LDLR on BBB endothelium | ApoE-coated EVs bind LDLR-mediated transcytosis | Preclinical |
| Transferrin Receptor | TfR1 | TfRVG peptide enables transcytosis | Phase 1 |
| LRP1 Targeting | LRP1 on BBB | Angiopep-2 peptide (TFFYGGSRGKRNNFKTE) | Preclinical |
| RVG Peptide | Nicotinic acetylcholine receptor | Rabies virus glycoprotein-derived | Preclinical |
| CD47 "Don't Eat Me" | Macrophage clearance | CD47 decoration reduces phagocytosis | Preclinical |
Source Cell Types for Therapeutic EVs:
| Cell Source | EV Characteristics | Advantages | Challenges |
|---|---|---|---|
| Mesenchymal Stem Cells (MSC) | Immunomodulatory, trophic factors | Clinical-grade production, safety | Variable potency |
| Neural Stem Cells (NSC) | Neurotrophic-rich, CNS-specific | Native CNS tropism | Limited expansion |
| iPSC-derived neurons | Patient-specific, tau-targeted | Autologous option | Manufacturing complexity |
| Monocytes/Macrophages | Anti-inflammatory (M2) | Natural brain homing | Requires polarization |
| Engineered HEK293 | High yield, consistent | Scalable production | Non-native composition |
Engineering Approaches:
Lipid Anchoring Techniques:
| Method | Application | Stability |
|---|---|---|
| Phosphatidylethanolamine (PE) conjugation | Amine-PEG-ligand anchors to EV membrane | Moderate |
| Cholesterol-PEG-ligands | Insertion into EV lipid bilayer | High |
| Acyl chain modification | Myristoylation/palmitoylation | High |
| GPI-anchored proteins | Natural membrane protein insertion | High |
Targeting Ligands:
| Ligand | Target | Application |
|---|---|---|
| RVG ( rabies virus glycoprotein) | Nicotinic AChR (neuronal) | Neuronal targeting |
| TfR-binding peptide | Transferrin receptor | BBB transcytosis |
| Angiopep-2 (TFFYGGSRGKRNNFKTE) | LRP1 | BBB + neuronal |
| RGD peptide | Integrins (αvβ3, α5β1) | Vascular endothelial |
| ApoE (full-length or domain) | LDLR/LRP1 | BBB crossing |
| SDF-1/CXCR4 | CXCR4 (neuroinflammation) | Inflammation targeting |
| cRGD | αvβ3 integrin | Tumor vasculature (for gliomas) |
Optimization Parameters:
Loading Methods:
| Method | Efficiency | Cargo Type | Preserves Function |
|---|---|---|---|
| Electroporation | 20-40% | siRNA, miRNA, small molecules | Moderate (membrane damage) |
| Sonication | 30-50% | Proteins, peptides | Variable |
| Extrusion | 40-60% | Proteins, drugs | Low (membrane fusion) |
| Freeze-thaw | 10-25% | Proteins | High |
| Co-incubation | <10% | Hydrophobic drugs | High |
| Passive loading | <5% | Hydrophilic drugs | High |
| Active loading (transfection) | 30-60% | mRNA, plasmid | High |
Therapeutic Cargo Types:
| Cargo | Therapeutic Goal | Loading Method | Status |
|---|---|---|---|
| Anti-tau siRNA/shRNA | Reduce tau expression | Electroporation | Preclinical |
| Anti-tau antibody fragments | Neutralize extracellular tau | Conjugation (surface) | Preclinical |
| GDNF mRNA | Local GDNF production | Electroporation | Preclinical |
| CDNF protein | Protein repair, ER stress | Sonication | Preclinical |
| Curcumin | Anti-inflammatory, antioxidant | Co-incubation | Preclinical |
| miR-124-3p | Neurogenesis promotion | Electroporation | Preclinical |
| Catalase | Antioxidant | Encapsulation | Preclinical |
Optimization Strategies:
Clinical-Stage Programs:
| Program | Company | Cargo | Target | Phase |
|---|---|---|---|---|
| ExoSTAT | ExoRNA Bio | miR-17-92 cluster | Treg modulation | Preclinical |
| iExosomes | Codiak | STING inhibitor | Cancer immunotherapy | Phase 1 |
| AGLETON | PureTech | siRNA | KRAS (cancer) | Phase 1 |
| MSC-EVs | Various | Mixed trophic factors | COPD, ARDS | Phase 1/2 |
| Neuralstem EV | Neuralstem | Neurotrophic factors | ALS | Preclinical |
Emerging CBS/PSP Targets:
EV Engineering Clinical Readiness:
| Component | Readiness | Score | Notes |
|---|---|---|---|
| Manufacturing scalability | Moderate | 3/5 | Upstream processing bottleneck |
| BBB crossing validation | Preclinical | 2/5 | Limited CNS pharmacokinetics data |
| Target specificity | Preclinical | 3/5 | Ligand optimization ongoing |
| Cargo loading efficiency | Moderate | 3/5 | 20-50% typical |
| Safety/toxicology | Phase 1 | 4/5 | MSC-EVs show good safety |
| Regulatory pathway | Emerging | 2/5 | No EV-specific FDA guidance |
| Cost | High | 1/5 | $10,000+ per dose estimated |
NET Score: 18/40 (45%) — Emerging technology, significant potential but requires development
| EV Therapy Component | Levodopa | Rasagiline | Interaction Risk |
|---|---|---|---|
| MSC-EVs | Minimal | Minimal | Low |
| Engineered EVs (TfR-targeted) | Minimal | Minimal | Low |
| EV-loaded small molecules | Variable | Variable | Depends on drug |
| EV-siRNA combinations | Minimal | Minimal | Low |
Interaction Considerations:
Assessment Protocol:
Current Recommendations:
| Priority | Intervention | Rationale | NET Score |
|---|---|---|---|
| Monitor | EV clinical trials | Watch for CBS/PSP programs | 18/40 |
| Low | MSC-EV therapy | Limited CNS data | 15/40 |
| Low | Engineered anti-tau EVs | Preclinical only | 12/40 |
| Low | EV-loaded GDNF | Research phase | 10/40 |
Patient-Specific Considerations:
Action Items:
More: Exosome Therapy | Exosome Drug Delivery CBS/PSP | EV Biomarkers